Testing palbociclib plus sasanlimab for advanced kidney cancers
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed advanced clear cell kidney cancer (with clear cell features) or papillary kidney cancer (with papillary features).
- Your cancer has at least one measurable spot that can be tracked on scans.
- For clear cell kidney cancer: you previously had a checkpoint inhibitor, and you either had (or could not receive) a VEGF-targeted treatment.
- Your age is 18 or older, and your general health is good enough for study treatment (ECOG 0–1).
- Your blood counts and organ tests are within required ranges (blood cells, kidney function, liver enzymes, and bilirubin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Hear when a new Advanced Clear Cell Renal Carcinoma (Ccrcc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.